Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Haematologica

Volumn 97, Issue 2, 2012, Pages 310-317

  Sureda, Anna ^a,b   Canals, Carme ^c   Arranz, Reyes ^d   Caballero, Dolores ^e   Ribera, Josep Maria ^f   Brune, Mats ^g   Passweg, Jacob ^h   Martino, Rodrigo ^a   Valcárcel, David ^a   Besalduch, Joan ⁱ   Duarte, Rafael ^j   León, Angel ^k   Pascual, Maria Jesus ^l   García Noblejas, Ana ^d   Corral, Lucia López ^e   Xicoy, Bianca ^f   Sierra, Jordi ^a   Schmitz, Norbert ^m  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c EBMT Office   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k HOSPITAL DE JEREZ   (Spain)

^l HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^m DEPARTMENT OF CARDIOLOGY   (Germany)

more..

Author keywords

Allogeneic stem cell transplantation; Hodgkin's lymphoma relapsed; Reduced intensity conditioning; Refractory

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; FLUDARABINE; MELPHALAN; THYROGLOBULIN ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LUNG HEMORRHAGE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE;

ADOLESCENT; ADULT; EUROPE; FEMALE; GRAFT VS HOST DISEASE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84856421828     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.045757     Document Type: Article

References (34)

1. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630-7.
2. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-95.
3. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341 (8852):1050-4.
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autolo-gous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323):2065-71.
5. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, et al. Autologous stem cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395-404.
6. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89(3):801-13.
7. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant. 1997;20(9):745-52.
8. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol. 2000;18(2):332-9.
9. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1999;17(10):3101-9.
10. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96(4):1280-6.
11. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al. Bone marrow transplants from HLA-identi-cal siblings in advanced Hodgkin's disease. J Clin Oncol. 1996;14(2):572-8.
12. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol. 1996;14(4): 1291-6.
13. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle Experience. J Clin Oncol. 1993;11(12):2342-50.
14. Akpek G, Ambinder R F, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, et al. Long-term results of blood and marrow transplantation for Hodgkin's disease. J Clin Oncol. 2001;19(23):4314-21.
15. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007; 21(11):2316-23.
16. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lym-phoma. Biol Blood Marrow Transplant. 2008;14(11):1279-87.
17. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus lymphoma effect after reduced intensity allogeneic transplantation. Lancet. 2005;365(9393):1934-41.
18. Alvarez I, Sureda A, Caballero D, Urbano-Ispizua A, Ribera JM, Canales M, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin's lymphoma: results of a Spanish Prospective Cooperative Protocol. Biol Blood Marrow Transplant. 2006;12(2): 172-83.
19. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-8.
20. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93(2): 257-64.
21. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3): 455-62.
22. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Meeting report. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-8.
23. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host-disease: 1. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12): 945-55.
24. Carbone PP, Kaplan HD, Musshogg K, Smithers DW, Tubiana M. Report of the Committee of Hodgkin's disease staging. Cancer Res. 1971; 31(11):1860-1.
25. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lym-phomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4): 1244-53.
26. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28(10):909-15.
27. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part II: regression modelling. Bone Marrow Transplant. 2001;28(11): 1001-10.
28. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-101.
29. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009;114 (10):2060-7.
30. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, et al. Unrelated donor reduced-intensity allo-geneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1):109-17.
31. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant. 2008;41(9):765-70.
32. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin's lym-phoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671-7.
33. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloabla-tive immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 2000;18(23):3918-24.
34. Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, et al. Prognostic role of PET scanning before and after reduced-intensity allogene-ic stem cell transplantation for lymphoma. Blood. 2010;115(14):2763-8.